TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Inoviq Ltd ( (AU:IIQ) ).
INOVIQ Ltd held its 2025 Annual General Meeting where all resolutions were passed by poll, reflecting strong shareholder support. This outcome is significant for the company’s strategic direction and may positively influence its market positioning in the cancer diagnostics and therapeutics industry.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology, focusing on advancing next-generation diagnostics and therapeutics to transform cancer care. Their product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 177,465
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$47.16M
For an in-depth examination of IIQ stock, go to TipRanks’ Overview page.